Monash IVF Group (MVF) H2 2024 earnings summary

Executive summary

• Underlying NPAT grew 17.4% to AUD 29.9 million, in line with guidance, while reported a net loss after tax of AUD 5.9 million due to a AUD 32.6 million post-tax impact from a class action settlement.

• Revenue rose 19.4% year-over-year to AUD 255.0 million, with all business segments—Domestic ARS/IVF, Ultrasound/Women's Imaging, and International—delivering robust growth and strong international rebound in the second half.

• Declared a fully franked final dividend of AUD 0.025 per share.

• Significant infrastructure investments and acquisitions, including Fertility North, supported growth.

• Clinical pregnancy rates improved by 1.5% to 40.5% for women under 43, and market share in Australia increased by 1.5% to 21.7%.

Financial highlights

• Underlying EBITDA rose 17.5% to AUD 62.8 million, with a stable EBITDA margin of 25%.

• Operating cash flow conversion was 104%, and free cash flow improved to AUD 13.7 million from negative AUD 1.4 million in FY23.

• Net debt increased by AUD 17.7 million to AUD 48.7 million, with leverage ratio at 0.9x and net debt to equity ratio at 19.7%.

• Goodwill rose by AUD 18 million due to the Fertility North acquisition.

• Underlying NPAT margin at 11.7%; return on equity improved to 10.7%.

Outlook and guidance

• Anticipates revenue and underlying NPAT growth in FY 2025, supported by full-year Fertility North contribution, new specialists, expanded day surgeries, genetics, donor activity, and international momentum.

• Ongoing focus on margin improvement, optimization, and enhancements to patient management systems.

• No specific quantitative guidance provided; further updates expected at the AGM in November.